302 related articles for article (PubMed ID: 23106273)
21. Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs.
Viveiros M; Martins M; Rodrigues L; Machado D; Couto I; Ainsa J; Amaral L
Expert Rev Anti Infect Ther; 2012 Sep; 10(9):983-98. PubMed ID: 23106274
[TBL] [Abstract][Full Text] [Related]
22. Baeyer-Villiger Monooxygenases EthA and MymA Are Required for Activation of Replicating and Non-replicating Mycobacterium tuberculosis Inhibitors.
Grant SS; Wellington S; Kawate T; Desjardins CA; Silvis MR; Wivagg C; Thompson M; Gordon K; Kazyanskaya E; Nietupski R; Haseley N; Iwase N; Earl AM; Fitzgerald M; Hung DT
Cell Chem Biol; 2016 Jun; 23(6):666-77. PubMed ID: 27321573
[TBL] [Abstract][Full Text] [Related]
23. Ethionamide cross- and co-resistance in children with isoniazid-resistant tuberculosis.
Schaaf HS; Victor TC; Venter A; Brittle W; Jordaan AM; Hesseling AC; Marais BJ; van Helden PD; Donald PR
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1355-9. PubMed ID: 19861006
[TBL] [Abstract][Full Text] [Related]
24. Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.
Fattorini L; Tan D; Iona E; Mattei M; Giannoni F; Brunori L; Recchia S; Orefici G
Antimicrob Agents Chemother; 2003 Jan; 47(1):360-2. PubMed ID: 12499213
[TBL] [Abstract][Full Text] [Related]
25. Fragment-Based Optimized EthR Inhibitors with
Villemagne B; Machelart A; Tran NC; Flipo M; Moune M; Leroux F; Piveteau C; Wohlkönig A; Wintjens R; Li X; Gref R; Brodin P; Deprez B; Baulard AR; Willand N
ACS Infect Dis; 2020 Mar; 6(3):366-378. PubMed ID: 32011115
[TBL] [Abstract][Full Text] [Related]
26. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea.
Lee H; Cho SN; Bang HE; Lee JH; Bai GH; Kim SJ; Kim JD
Int J Tuberc Lung Dis; 2000 May; 4(5):441-7. PubMed ID: 10815738
[TBL] [Abstract][Full Text] [Related]
27. Modification of proportion sensitivity testing method for ethionamide.
Lakshmi R; Ramachandran R; Devika K; Radhika G; Syam Sundar A; Rahman F; Selvakumar N; Kumar V
World J Microbiol Biotechnol; 2013 Jun; 29(6):1117-9. PubMed ID: 23315266
[TBL] [Abstract][Full Text] [Related]
28. Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
Nikiforov PO; Blaszczyk M; Surade S; Boshoff HI; Sajid A; Delorme V; Deboosere N; Brodin P; Baulard AR; Barry CE; Blundell TL; Abell C
ACS Chem Biol; 2017 May; 12(5):1390-1396. PubMed ID: 28314097
[TBL] [Abstract][Full Text] [Related]
29. Reversion of antibiotic resistance in
Blondiaux N; Moune M; Desroses M; Frita R; Flipo M; Mathys V; Soetaert K; Kiass M; Delorme V; Djaout K; Trebosc V; Kemmer C; Wintjens R; Wohlkönig A; Antoine R; Huot L; Hot D; Coscolla M; Feldmann J; Gagneux S; Locht C; Brodin P; Gitzinger M; Déprez B; Willand N; Baulard AR
Science; 2017 Mar; 355(6330):1206-1211. PubMed ID: 28302858
[TBL] [Abstract][Full Text] [Related]
30. High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations.
Machado D; Perdigão J; Ramos J; Couto I; Portugal I; Ritter C; Boettger EC; Viveiros M
J Antimicrob Chemother; 2013 Aug; 68(8):1728-32. PubMed ID: 23539241
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of sparfloxacin in combination with kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis patients: preliminary results.
Singla R; Gupta S; Gupta R; Arora VK
Int J Tuberc Lung Dis; 2001 Jun; 5(6):559-63. PubMed ID: 11409584
[TBL] [Abstract][Full Text] [Related]
32. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs.
Toungoussova OS; Mariandyshev AO; Bjune G; Caugant DA; Sandven P
Eur J Clin Microbiol Infect Dis; 2005 Mar; 24(3):202-6. PubMed ID: 15742171
[TBL] [Abstract][Full Text] [Related]
33. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.
Rengarajan J; Sassetti CM; Naroditskaya V; Sloutsky A; Bloom BR; Rubin EJ
Mol Microbiol; 2004 Jul; 53(1):275-82. PubMed ID: 15225321
[TBL] [Abstract][Full Text] [Related]
34. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study.
Penn-Nicholson A; Georghiou SB; Ciobanu N; Kazi M; Bhalla M; David A; Conradie F; Ruhwald M; Crudu V; Rodrigues C; Myneedu VP; Scott L; Denkinger CM; Schumacher SG;
Lancet Infect Dis; 2022 Feb; 22(2):242-249. PubMed ID: 34627496
[TBL] [Abstract][Full Text] [Related]
35. Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide.
Huang TS; Lee SS; Tu HZ; Huang WK; Chen YS; Huang CK; Wann SR; Lin HH; Liu YC
J Antimicrob Chemother; 2004 Apr; 53(4):600-3. PubMed ID: 14973155
[TBL] [Abstract][Full Text] [Related]
36. Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study.
Jacobson KR; Barnard M; Kleinman MB; Streicher EM; Ragan EJ; White LF; Shapira O; Dolby T; Simpson J; Scott L; Stevens W; van Helden PD; Van Rie A; Warren RM
Clin Infect Dis; 2017 Jun; 64(11):1502-1508. PubMed ID: 28199520
[TBL] [Abstract][Full Text] [Related]
37. Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis.
Heifets LB; Lindholm-Levy PJ; Flory M
Am Rev Respir Dis; 1991 Feb; 143(2):268-70. PubMed ID: 1899326
[TBL] [Abstract][Full Text] [Related]
38. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda.
Umubyeyi A; Rigouts L; Shamputa IC; Dediste A; Struelens M; Portaels F
Int J Infect Dis; 2008 Mar; 12(2):152-6. PubMed ID: 17950021
[TBL] [Abstract][Full Text] [Related]
39. New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains.
Ristow M; Möhlig M; Rifai M; Schatz H; Feldmann K; Pfeiffer A
Lancet; 1995 Aug; 346(8973):502-3. PubMed ID: 7637495
[No Abstract] [Full Text] [Related]
40. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Kam KM; Yip CW
Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
